Prescription and Management of Patient Controlled Intravenous Analgesia - No Longer Applicable - Superseded by MP 0131/20 - 10 February 2020

Applicable to: All Department of Health Staff involved in the Prescription and Management of Patient Controlled Intravenous Analgesia.

Description: This policy is intended for use in all Western Australian public hospitals and departments where intravenous patient controlled intravenous analgesia (PCIA) is prescribed. It aims to ensure that prescription, administration and monitoring of PCIA is safe and appropriate. This document describes the minimum standards for the provision of routine PCIA care, focusing on opioid use and associated patient care.

The document is not able to encapsulate all peculiarities of individual patient presentations or care and in each instance therapy and monitoring is to be adjusted for the individual patient’s needs. An exemplar, include high-risk patients (e.g. those with head injuries, pre-existing respiratory disease such as obstructive sleep apnoea, or renal/hepatic failure) requiring more intensive monitoring or dose adjustment, which is out of this document’s scope.

Prescription and Management of Patient Controlled Intravenous Analgesia

This policy is intended for use in all Western Australian public hospitals and departments where patient controlled intravenous analgesia is prescribed. It aims to ensure the prescription, administration and monitoring of patient controlled intravenous analgesia is safe and appropriate. This document describes the minimum standards for the provision of routine patient controlled intravenous analgesia care, with a focus on opioid use and associated patient care.

The document is not able to encapsulate all peculiarities of individual patient presentations or care and in each instance therapy and monitoring is to be adjusted for the individual patient’s needs. An exemplar, includes high-risk patients (e.g. those with head injuries, pre-existing respiratory disease such as obstructive sleep apnoea, or renal/hepatic failure) requiring more intensive monitoring or dose adjustment.


Dr D J Russell-Weisz
DIRECTOR GENERAL
DEPARTMENT OF HEALTH WA

Date of effect: 15 November 2015 to 10 February 2020

Policy Framework

Related documents